Ronald L Shazer MD
Hospital Medicine/Hospitalist
Vice President, Clinical Development
Join to view full profile
3545 Cray CtSan Diego, CA 92121
Phone+1 858-529-7039
Dr. Shazer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ronald Shazer is an internist in San Diego, CA. He received his medical degree from New York Medical College and has been in practice 16 years. He specializes in hospital medicine/hospitalist and is experienced in hospitalist medicine, health technology/informatics, and oncology clinical research.
Education & Training
UCLA Anderson School of Management MBA, 2005 - 2007
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2001 - 2004
New York Medical CollegeClass of 2001
Certifications & Licensure
CA State Medical License 2002 - 2026
Clinical Trials
Publications & Presentations
PubMed
- 81 citationsSAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W S M E Theelen
Annals of Oncology. 2024-01-01 - 126 citationsMRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut
Cancer Discovery. 2023-11-01 - 31 citationsMRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno
Journal of Thoracic Oncology. 2023-07-01
Press Mentions
First Patient Dosed in Pivotal Biomarker-Guided Phase 3 Study of First Line Therapy with DB102 (Enzastaurin) + R-CHOP in Patients with High-Risk Diffuse Large B-cell Lymphoma (DLBCL)April 3rd, 2018- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop HospitalOctober 4th, 2017
- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of MedicineOctober 2nd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: